Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

CBD

  • Home
  •  
  • CBD



  • Most Read
  • Latest Comments
  • Can cannabis cure insomnia? Avecho gets ethics approval to test in Phase 3 trials
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Can cannabis cure insomnia? Avecho gets ethics approval to test in Phase 3 trials
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Can cannabis cure insomnia? Avecho gets ethics approval to test in Phase 3 trials
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Can cannabis cure insomnia? Avecho gets ethics approval to test in Phase 3 trials
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Can cannabis cure insomnia? Avecho gets ethics approval to test in Phase 3 trials
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • ECS Botanics secures distribution rights to bring Terphogz’s ‘The Original Z’ cannabis strain to Australia
    ECS Botanics secures distribution rights to bring Terphogz’s ‘The Original Z’ cannabis strain to Australia
    • News

  • Bioxyne leads the way as Australia’s first manufacturer of pharmaceutical cannabis gummies
    Bioxyne leads the way as Australia’s first manufacturer of pharmaceutical cannabis gummies
    • News

  • Melodiol moves to clear debt with $12m asset fire sale
    Melodiol moves to clear debt with $12m asset fire sale
    • News

  • Althea to make a splash in the US with new cannabis-based sodas
    Althea to make a splash in the US with new cannabis-based sodas
    • News

  • Melodiol Global Health reports revenue growth amid wider acceptance of medicinal cannabis products
    Melodiol Global Health reports revenue growth amid wider acceptance of medicinal cannabis products
    • News

  • Can cannabis cure insomnia? Avecho gets ethics approval to test in Phase 3 trials
    • News

    Can cannabis cure insomnia? Avecho gets ethics approval to test in Phase 3 trials

    For many, a bad night’s sleep can be chalked up to a late night out, stress and such. However, multiple nights of restless sleep could mean something more. Insomnia is among the two most common sleep disorders in Australia, with the second being obstructive sleep apnea. About 60% of Aussies display symptoms of insomnia. With

    Read More
    Public
  • ECS ditches new cartridges to enter vapes and pastilles market
    • News

    ECS ditches new cartridges to enter vapes and pastilles market

    As of early 2023, over three million Aussies aged 14 and above were found to either smoke or vape. With a greater number of teens and young Aussies taking up vaping, it has created a massive potential market for cannabis cultivators and manufacturers like ECS Botanics (ASX: ECS). ECS is launching a range of GMP-certified

    Read More
    Public
  • Bod Science’s Aqua Phase cannabis outperforms oil-based cannabis in absorption, concentration and onset speed
    • News

    Bod Science’s Aqua Phase cannabis outperforms oil-based cannabis in absorption, concentration and onset speed

    Traditional cannabis in the form of oil has had an absorption problem, making it less effective. But what if you blended it with starch, which boasts greater absorption without messing with the compound? Cannabis-focused drug development company Bod Science (ASX: BOD) undertook a study on the same, delivering some positive results. So positive, in fact,

    Read More
    Public
  • Cannabis lemonade and iced teas: Althea’s Peak teams up with Tweed to bring cannabis-infused products to Canada
    • News

    Cannabis lemonade and iced teas: Althea’s Peak teams up with Tweed to bring cannabis-infused products to Canada

    Cannabis is the most widely-used illicit drug worldwide; about 2.5% of the world, i.e. approximately 150 million people, consume cannabis, and Australia is among the top countries leading the trend. While it sounds the alarm on the concerning drug abuse problem, it also signals a profitable market for companies in the field.   Cannabis-based medicine and

    Read More
    Public
  • Avecho develops cannabis gummies, gears up to bring them to Australia
    • News

    Avecho develops cannabis gummies, gears up to bring them to Australia

    Biotech company Avecho (ASX: AVE) has completed the development of its first generation TPM gummies containing cannabinoids and is all set to release them to Aussie consumers. TPM cannabinoid gummies out-perform standard products with faster onset and greater magnitude of effect. Gummies are chewable, jelly-like preparations made from a mixture of glycerin and gelatin, able

    Read More
    Public
  • Cann’d: clinical trials show no difference between cannabis capsules and placebo
    • News

    Cann’d: clinical trials show no difference between cannabis capsules and placebo

    Since the easing of regulatory red tape and wider societal acceptance of utilising cannabis for its medical properties, the medicinal cannabis industry has become an intense battleground as researchers have raced towards commercial products. In the case of Cann Group (ASX: CAN) though, they might have just triggered a land mine.  Undertaking any form of

    Read More
    Public
  • 1
  • 2

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.